SCK•CEN authors are displayed in bold
|Title:||Preclinical development of 68Ga-labelled aptamers for molecular cancer imaging|
molecular cancer imaging
|Publication type:||Promoted work|
|Citation:||Gijs M.- Preclinical development of 68Ga-labelled aptamers for molecular cancer imaging.- Liege, Belgium: ULg, 2015.- 181 p.- PhD thesis|
|Abstract:||Breast cancer is the most common cancer in women worldwide. About 1 in 8 women will develop invasive breast cancer during their lifetime. Breast cancer is the second leading cause of cancer death in women, after lung cancer. Approximately 20-25% of breast cancer cases overexpress the HER2 receptor. Currently, the HER2 status of a tumour is assessed by tumour biopsy and subsequent immunohistochemistry. However, small biopsies may not be representative of the entire tumour mass or metastases (due to tumour heterogeneity), risking misclassification and selection of suboptimal therapies. Molecular imaging of HER2 could potentially overcome these limitations by providing information at the whole body-level in a fast and non-invasive way. This PhD thesis aimed at developing novel aptamer-based radiopharmaceuticals for molecular imaging of HER2-positive cancer at the preclinical level.|
Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.